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Background: The number of antipsychotic prescriptions dispensed annually in England has 
increased substantially over the past decade. It is not known whether this is due to changes in 
prescribing practices, or an increase in the prevalence of psychosis. To our knowledge, no previous 
studies have investigated temporal trends in prevalence of psychotic symptoms in non-clinical 
populations.  
	
Methods: We used data from the nationally representative Adult Psychiatric Morbidity Surveys 2000, 
2007 and 2014 to (1) test whether the prevalence of psychotic symptoms increased between 2000 
and 2014; (2) compare prevalence of psychotic symptoms to the prevalence of being prescribed 
antipsychotic medication; and (3) identify correlates of experiencing psychotic symptoms.   
	
Results: There was a small increase in the prevalence of psychotic symptoms in 2014 compared to 
2000 (Prevalence in 2000 5.6%, 95% confidence intervals (CI) 5.1% to 6.2%; prevalence in 2014 
6.8%, 95% CI 6.1% - 7.6%). This corresponded to an adjusted odds ratio of 1.2 (95% CI 1.02 - 1.40, 
p=0.026) for experiencing psychotic symptoms in 2014 compared to 2007. By comparison, 
antipsychotic medication use doubled over this period (Prevalence in 2000 0.6%, 95% CI 0.4% - 
0.7%; prevalence in 2014 1.2% 95% CI 0.9% - 1.5%; aOR 2.22 (1.52-3.25) p<0.001). Correlates of 
reporting psychotic symptoms included ethnic minority identity, younger age, lower social class, 
alcohol and cannabis use, and any psychiatric diagnosis.  
	
Conclusions: While the rates of antipsychotic prescription doubled between 2000 and 2014, the 










Psychotic symptoms include perceptual abnormalities and delusional beliefs such as firmly-
held persecutory ideation (Bourgin et al., 2019). When pronounced and sustained, these symptoms, 
along with other problems of thinking and emotion, may indicate psychotic illnesses like 
schizophrenia (Kirkbride et al., 2012). People who experience psychotic symptoms are known to be at 
greater risk of developing these illnesses than the rest of the population (Andreou et al., 
2019). Nevertheless, many individuals experience psychotic symptoms without meeting the criteria for 
a diagnosable psychotic illness (Bourgin et al., 2019, Wiles et al., 2006); indeed a majority 
of people identified from screening tools as having psychotic symptoms are unlikely to be given a 
diagnosis of psychotic illness (Bourgin et al., 2019).  
	
Psychotic symptoms have been found to be associated with younger age, migrant status, 
lower socioeconomic status, trauma, and drug and alcohol use (Bourgin et al., 2019, Scott et al., 
2005, Sun et al., 2017, Gibson et al., 2016), though not with a family history of schizophrenia (Zammit 
et al., 2008). They are frequently comorbid with other psychiatric problems, including depression, 
anxiety, and non-suicidal self-injury (Bourgin et al., 2019, Koyanagi et al., 2015, Saha et al., 2012). It 
appears therefore that the correlates of psychotic symptoms overlap largely but not entirely with those 
of psychotic illnesses (Bourgin et al., 2019); a finding which warrants confirmation across samples. If 
the correlates of psychotic symptoms in general populations are different to those of psychotic 
illnesses, this suggests that they may represent a different phenomenon rather than lying on a 
continuum with illness. 
	
The 2014 Adult Psychiatric Morbidity Survey (APMS) aimed to establish prevalence of psychiatric 
illnesses in the population of England and found that rates of ‘probable psychosis’ had roughly 
doubled between 2007 and 2014. The APMS however used antipsychotic prescription as one of 
several indicators of probable psychosis, which may have artificially increased the prevalence 
(McManus et al., 2016). Understanding whether the prevalence of psychotic disorders and symptoms 
is increasing is crucial to the appropriate planning of services and the employment of preventive 
strategies. There have been attempts to study changes in the frequency of psychotic illness, albeit 
with inconsistent findings. A systematic review of the incidence and prevalence of psychotic disorders 
in England found no convincing evidence that psychotic illnesses had increased between 1950 and 
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2009 (Kirkbride et al., 2012). In contrast, an investigation based on UK electronic health records did 
find an increase in the incidence of diagnosed psychotic illnesses between 1996-1999 and 2010-
2012, which varied in different ethnic groups (Oduola et al., 2019). 
 
We aimed to test the hypothesis that the prevalence of psychotic symptoms in England increased 
between 2000 and 2014 and to to compare any change in symptom prevalence to the prevalence of 
being prescribed antipsychotic medication between 2000 and 2014. We also 
aimed to identify correlates for experiencing psychotic symptoms to see whether these overlapped 
with known correlates of psychotic illness, thereby strengthening the assumption that they might be a 
reasonable proxy for psychotic disorder in the sample. We know of no other studies of changes in the 
























The Adult Psychiatric Morbidity Surveys (APMS) are nationally-representative surveys that have been 
conducted at seven yearly intervals to quantify the prevalence of psychiatric symptoms and disorders 
in the population of England, and are designed to be representative of people living in private 
households (McManus et al., 2019). They have used a consistent stratified, multi-stage 
probability sample design. APMS methodology has been described in detail elsewhere (McManus et 
al., 2016). In brief, the Postcode Address File, which covers over 97% of private households, was 
used as the sampling frame. Postcode sectors were stratified according to sociodemographic 
variables and selected using systematic random sampling. Households were then randomly selected 
within each chosen postcode sector, and one resident was randomly selected for interview from 
each chosen household. The interviews took approximately 1.5 hours and combined face-to-face 
questions with computer-inputted questions for sensitive topics. Weighting adjusted for selection 
probabilities and patterns of non-response in order to render results representative of the household 
population. 	
		
The 2007 and 2014 APMS samples consist of around 7,500 people in England aged 16 and 
over (McManus et al., 2016). The 2000 survey used similar methods but also covered Scotland and 
Wales and had an upper age limit of 74. To ensure comparability, only respondents aged 16 to 74 
and living in England were included in the current study.  
	
Exposures:  	
We used year of measurement (2000, 2007, or 2014) as the exposure variable for the primary 




Psychotic Symptoms  
The Psychosis Screening Questionnaire (PSQ) has high sensitivity and specificity for detecting 
psychotic symptoms across populations with differing likelihoods of psychosis (Bebbington and 
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Nayani, 1995). It contains five sections, each with three or four questions and a set of rules for 
interpretation (Bebbington and Nayani, 1995). It can be used as a continuous or a binary 
measure. Consistent with standard practice we took endorsement of one or more clusters to indicate 
the presence of psychotic symptoms (Johns et al., 2004), thereby forming a binary outcome 
variable. We also carried out a sensitivity analysis, using the stricter criterion of endorsing two or more 
clusters to measure this outcome. 	
	
Antipsychotic Medication Use 	
In 2000 participants, were asked to list medications they were currently taking. Interviewers coded all 
medications that were reported. In 2007, participants were shown a prompt-list of psychotropic 
medications and asked which if any they were taking. Interviewers then inspected medication 
packaging to check that it was correctly coded. In 2014 the same method was used, although the list 
was expanded and amended to reflect an up-to-date psychotropic medication inventory (McManus et 
al., 2016).	
 
Potential Correlates for Psychotic Symptoms  	
We analysed: age (in 10 year brackets); sex; ethnicity (White British / Black or African or Caribbean or 
Black British / Indian or Pakistani or Bangladeshi or Asian or Asian British / Other); socioeconomic 
status; reported diagnosis of psychiatric illness; reported lifetime history of a major traumatic 
experience; reported cannabis use in the past year; and the Alcohol Use Disorders Identification Test 
(AUDIT) score (Saunders et al., 1993) as potential correlates associated with reporting psychotic 
symptoms. Socioeconomic status was classified in one of the following groups: 1=Employers in large 
establishments, higher managerial and professional occupations; 2= Lower professional, higher 
technical, lower managerial and administrative, and higher supervisory occupations; 3= Intermediate 
occupations; 4= Employers in small occupations and own account workers; 5=Lower supervisory and 
lower technical occupations, or; 6 / 7=Semi-routine occupations and routine occupations (Office for 
National Statistics, 2010). Lifetime experience of trauma was established through the following 
question: The term traumatic event or experience means something like a major natural disaster, a 
serious automobile accident, being raped, seeing someone killed or seriously injured, having a loved 
one die by murder or suicide, or any other experience that either put you or someone close to you at 
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risk of serious harm or death. Has a traumatic event or experience ever happened to you at any time 
in your life (Brewin et al., 2002, McManus et al., 2016)?  
 
These putative correlates were chosen because of known associations with psychotic illnesses c  
 
Analyses were conducted using pooled data from the 2000, 2007 and 2014 surveys. Reported 
diagnoses from a professional had only been recorded in the 2014 sample, and therefore was only 
analysed in this dataset. Similarly, lifetime experience of major trauma was not measured in the 2000 
sample, meaning that this analysis was restricted to 2007 and 2014 data. Socioeconomic status was 
measured differently across years, and so was analysed only in 2014 data.  
 
Statistical Analyses:  
Data were analysed using Stata version 16 (StataCorp). We combined the three datasets for analysis. 
The proportion of participants in different years reporting at least one cluster of psychotic 
symptoms was compared. We used the svy function in Stata to preserve the APMS survey weighting 
in these analyses. All tables show weighted analyses and unweighted (true) base numbers. For the 
2007 and 2014 datasets, we were also able to account for complex survey design (stratification and 
clustering). For 2000, we were able to account for stratification by region.  
 
We then used logistic regression models to compare the odds of each outcome (positive PSQ result, 
and reported antipsychotic medication use) according to year of exposure. We restricted this analysis 
to participants who lived in England, were aged under 75, and had provided data on their ethnicity for 
comparability across the datasets. We carried out these analyses unadjusted, then adjusted for age, 
gender and ethnicity, to account for changes in the sample demographics over time. We included 
ethnicity because black men were found to have a higher prevalence of psychotic disorder (3.2%) 
compared to men from other ethnic groups: 0.3% in White men and 1.3% in Asian men (McManus et 
al., 2016, Qassem et al., 2015).  
	
In order to establish potential correlates of psychotic symptoms in the sample, we used logistic 
regression to model the unadjusted odds ratios of reporting psychotic symptoms according to the 
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putatively associated demographic and health variables. We performed these analyses unadjusted, 































The demographic characteristics of the sample are shown in Table 1. 
The population profile has been broadly consistent over time, except for a decrease in the proportion 
who were from a White ethnic group (from 92.9% to 86.4%), and an increase in the proportions who 
were married/cohabiting (from 58.0% to 62.9%) and living in rented accommodation (from 25.3% to 
37.3%).  
 
Psychotic symptoms (Tables 2 and 3)  
The prevalence of psychotic symptoms (as determined by the PSQ) increased between 
surveys. Logistic regression provided statistical evidence of a small increase in reports of psychotic 
symptoms between 2000 and 2014, both before and after adjustment for age, gender and 
ethnicity (Adjusted Odds Ratio (aOR) 1.20, 95% Confidence Interval (CI) 1.02 to 1.40, p= 
0.026). There was no evidence of a change between 2000 and 2007, showing that the increase 
occurred between 2007 and 2014. 
 
Sensitivity analysis 
When the outcome was endorsement of two PSQ items rather than just one, there was still evidence 
of an increase between 2000 and 2014, both before and after adjustment (OR 1.44 (1.04 – 1.98, 
p=0.026, aOR 1.39, 95% CI 1.01 - 1.92, p=0.046).  	
 
Rates of Antipsychotic Prescription (Tables 2, 3 and 4) 	
Both crude and weighted estimates of antipsychotic medication use increased only slightly between 
2000 and 2007, but approximately doubled between 2000 and 2014, both before and after adjusting 
for age, gender and ethnicity (aOR 2.22 95% CI 1.52 - 3.25, p<0.001). Again, this increase must 
therefore have occurred between 2007 and 2014. The proportion of people both with and without 
psychotic symptoms prescribed antipsychotic medication increased between 2007 and 2014. 3.1% of 
people reporting psychotic symptoms also reported antipsychotic medication use in 2000, compared 





Putative Correlates for Experiencing Psychotic Symptoms (Table 5)  
There was strong evidence that lifetime experience of major trauma, reported diagnosis of any mental 
illness, increasing AUDIT score, and past year cannabis use were associated with screening positive 
on the PSQ. Having been given a diagnosis of schizophrenia or psychosis was, as might be 
expected, strongly associated with a positive PSQ result (OR 14.98, 95% CI 7.26 - 30.89, 
p<0.001). People describing themselves as Asian or British Asian had a somewhat increased 
odds of psychotic symptoms compared to people describing themselves as White British (OR 1.49, 
95% CI 1.07 – 2.07, p=0.019). There was strong evidence that people describing themselves as 
Black, African, Caribbean, or Black British had greater odds of reporting psychotic symptoms 
compared to people reporting White British ethnicity (OR 2.22, 95% CI 1.61 – 3.05, p<0.001). Being in 
routine/semi-routine and lower supervisory employment was strongly associated with greater odds of 
a positive PSQ result compared to being in social class 1. There was strong evidence that all age 
groups above age 24 had lower odds of screening positive on the PSQ compared to 16-24 year olds; 
in the 65-74 year old group, the odds ratio was just 0.26 (95% CI 0.19 – 0.35, p<0.001). There was no 




















We found evidence for a relatively small increase in the prevalence of psychotic symptoms between 
2000 and 2014 in England. In contrast, the frequency of antipsychotic medication prescription 
approximately doubled over the same period. These increases appear to have occurred between 
2007 and 2014.  
 
There are multiple possible explanations for this pattern of results. The first is that the prevalence of 
psychotic disorders may genuinely have increased by a large margin. The lack of a proportionate rise 
in psychotic symptoms could be due to a large number of people whose symptoms are in remission, 
perhaps due to effective treatment, or who have only negative symptoms that could not be detected 
by the PSQ. This would be consistent with the findings from the 2019 study of incidence rates of first 
episode psychosis (Oduola et al., 2019). However development of Early Intervention (EIS) services 
could have partially explained the apparent increase rates in this study through greater case 
identification (Oduola et al., 2019).  
 
This explanation would also suggest that a large number of people had developed psychotic disorders 
after 2007 but were asymptomatic (in terms of positive symptoms) by 2014, which seems reasonably 
unlikely, given that roughly half of people with a first-episode of psychosis do not show symptomatic 
recovery after two years (Wunderink et al., 2009).  
 
An alternative, more likely explanation is that the apparent increase in probable psychosis in the 
APMS is a measurement artefact, since receipt of antipsychotic medication was one criterion used to 
determine probable psychosis. This would be more consistent with the findings from the 2012 
systematic review of studies reporting psychotic illness incidence (Kirkbride et al., 2012). For 
example, our finding that antipsychotic medication use has increased at almost double the rate of 
psychotic symptoms might indicate a greater readiness to recognise and treat psychotic symptoms, 
due to improved awareness of mental illnesses among healthcare professionals and the wider public. 
It may also indicate decreased stigma. A combination of 2001 healthcare policy influencing 
development of EIS services (Fowler et al., 2009) and greater appreciation of the importance of 
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minimising the duration of untreated psychosis may have played a part (Malla and McGorry, 2019). 
Increased use of antipsychotic medications may also be attributable to second generation 
antipsychotics becoming more widely available since their development in the 1990s (Shen, 
1999), and a consequent perception of a reduced side effect burden (Cáceres et al., 2008). The 
duration of prescribing may have increased too. Newer antipsychotics have been found to have better 
tolerability, which may mean an increased willingness to continue treatment (Swartz et al., 2008). 
Nevertheless, the finding that the prevalence of antipsychotic medication use did not increase 
markedly between 2000 and 2007 goes against increased duration of use being the reason.	
	
The increased prescribing of antipsychotic medications may also be due to indications other than 
psychosis. For example, antipsychotic medications may be indicated for mood stabilisation in bipolar 
affective disorder; and as augmentation therapies in depression, obsessive-compulsive disorder, and 
anxiety disorders; and as antiemetics (Glick et al., 2001, Jackson and Tavernier, 2003). This is 
consistent with our finding that the proportion of people without psychotic symptoms using 
antipsychotic medications increased between 2007 and 2014. 
 
While not of the magnitude of the rise in antipsychotic treatment, the modest rise in the prevalence of 
psychotic symptoms in the population of England also warrants explanation. Cannabis was the most 
commonly used recreational drug in the APMS with an estimated prevalence of use of 9.4% in men 
and 5.1% in women (McManus et al., 2016). The frequency of cannabis use has been broadly stable 
over time, but the content of tetrahydrocannabinol (THC) in cannabinoids has increased (Murray et 
al., 2016). THC is particularly implicated in causing psychotic symptoms, and this might therefore be 
one explanation for the slight increase in prevalence of psychotic symptoms. The economic 
recession that began in the UK in 2008 was paralleled by an increase in the incidence of suicide (Barr 
et al., 2012), an indicator of the accompanying stress. Economic adversity might also therefore be a 
plausible contributor to the increase in prevalence of psychosis (Kirkbride et al., 2017). Prevalence 
rates could also have increased due to improved survival rates of people with psychosis. There has 
been increasing recognition of and emphasis on reducing the mortality gap for people with serious 
mental illness compared to those without, which could account for this (Zomer et al., 2017). Reduced 
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recovery rates could be a further explanation, though this seems less likely given the increase in 
treatment. 
 
Screening positive on the PSQ in the 2014 APMS was associated with several factors including ethnic 
minority status, younger age, drug and alcohol use, trauma, lower social class, and psychiatric 
diagnoses. This is consistent with previous literature (Bourgin et al., 2019, Sun et al., 2017, Scott et 
al., 2005, Gibson et al., 2016). 
	
Although the data are cross-sectional, the increased reporting of psychotic symptoms in the 16-24 
age group suggests that such symptoms in adolescence or young adulthood may remit later on. This 
is consistent with findings from longitudinal data (Sullivan et al., 2017). There was no association of 
psychotic symptoms with gender, which was unexpected, given psychotic illness is generally 
considered to be more prevalent in men (Castillejos et al., 2018). These findings lend some weight to 
the argument that psychotic symptoms might represent a different phenomenon to psychotic 
symptoms seen in illnesses such as schizophrenia in a substantial proportion of survey participants 
(Zammit et al., 2008) , though it is clear that there is marked overlap in the correlates too (Sun et al., 
2017, Gibson et al., 2016, Scott et al., 2005). 
 
Strengths and Limitations 	
To our knowledge, this is the first study to measure temporal trends in the general population 
prevalence of psychotic symptoms. Its strengths include the use of nationally representative 
population-based surveys and the capacity to compare different methods of measuring psychosis. It 
also has limitations. As with most surveys, non-response was a potential cause of bias. The response 
rate was just under 70% in 2000; and was 57% in both 2007 and 2014. This is consistent with 
other large surveys (McManus et al., 2016). The APMS series excludes the relatively small number of 
people living in institutions including care homes and prisons, as well as homeless people and those 
in temporary accommodation or hospital. It may thus somewhat underestimate the rates of psychotic 
illnesses, given they are higher in those populations. Cuts in the number of mental health beds and 
prison beds since 2000 would have tended to increase the proportion of people identified as having 
psychotic symptoms in the community (The King's Fund). Response bias is also possible, for example 
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if people with psychotic symptoms were more distressed and therefore less likely to respond to the 
request to be interviewed. This should however have affected all years similarly. 
	
The measurement of antipsychotic medication use was by self-report. Nevertheless, the finding that 
rates of antipsychotic prescription have increased and therefore might explain the apparent increase 
in probable psychosis accords with recorded rates of dispensing of antipsychotic medication (Web 
appendix 1). Although the use of a screening tool to determine the presence of psychotic symptoms is 
less reliable than a structured clinical interview, it is the only feasible way to do this in a large non-
clinical population.  
 
The fact that antipsychotic medication use was measured differently between years could theoretically 
have meant that more antipsychotic prescriptions were detected in 2007 and 2014 than in 2000. 
However, our trends in self-reported medication use mirror those from prescribing data.  
Conclusions	
Our study suggests that the prevalence of psychotic symptoms has increased slightly in England 
since 2007. Continued monitoring of temporal trends in psychotic symptoms and psychotic illnesses is 
warranted. It is clear, however, that the frequency of psychotic symptoms has not increased 
proportionately to rates of antipsychotic medication prescription. This may signify that more people 
are being appropriately offered treatment for psychotic and other psychiatric illnesses; or alternatively 
that there has been a shift towards greater medicalisation of people with psychotic symptoms that 
may or may not be beneficial. Given the significant side effect burden of antipsychotic medications 
and the marked increase in their use, it crucial that prescriptions are reviewed regularly and that the 






















3239 (46.5)  
  
2828 (49.4)  
  
2640 (49.6)  
Age  
16-24   
25-34   
35-44   
45-54   
55-64   
65-74   
  
666 (12.6)  
1443 (18.9)  
1540 (20.9)  
1331 (19.9)  
1195 (15.7)  
1072 (12.0)  
  
568 (15.5)  
1035 (18.1)  
1413 (21.2)  
1130 (17.7)  
1279 (16.3)  
1028 (11.3)  
  
560 (15.7)  
1035 (18.7)  
1180 (17.9)  
1294 (19.3)  
1226 (15.4)  




6741 (92.9)  
 
  
5884 (88.9)  
 
 
5785 (86.4)  
  
Black  
Indian, Pakistani or Bangladeshi, Asian or Asian British  
Other   
179 (2.2)  
136 (2.4)  
142 (1.9)  
183 (3.3)  
196 (4.2)  
        157 (3.2)  
 
182 (3.2)  
345 (7.6)  
147 (2.8) 
Missing 
49 (0.6) 33 (0.5) 25 (0.4) 
Marital Status ʈ  
Married / Cohabiting  
Single / Widowed / Divorced / Separated  
  
3700 (58.0)  
3547 (42.0)  
  
3817 (64.4)  
2636 (35.6)  
  
3751 (62.9)  
2733 (37.1)  
Housing Tenure  
Owner-occupier  
Rent or other  
Missing 
  
5183 (73.9)  
2001 (25.3)  
		
4520 (69.5)  
1887 (29.7)  
  
4111 (62.0)  
2328 (37.3)  
63 (0.9) 46 (0.8) 45 (0.8) 
Cannabis Use in Past Year  
Used in past year 
Missing 
  
581 (8.5)  
  
411 (8.1)  
  
377 (7.4)  
32 (0.4) 25 (0.5) 438 (6.4) 
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Alcohol Use Disorder Identification Test (AUDIT) Score  
(Mean and standard deviation)  5.2 (4.6)  4.8 (4.7)  4.4 (4.7)  
Missing (%) 36 (0.4) 11 (0.2) 209 (3.0) 
 	
ʅ Sample = APMS participants aged 16 to 74 and living in England  	


























Table 2: Prevalence of Psychotic Symptoms and Current Antipsychotic Prescription, 2000, 2007 and 
2014 for Analytic Sample	
	
Year  Total Sample 
(N) 
Number of cases 
(n) 
Missing Outcome Data 
(n) 
Prevalence (%) 
(95% Confidence Interval 
(CI))  
Psychotic Symptoms 
2000 7198 431  0  5.58 (5.05 – 6.18)  
2007 6406 387  14  5.89 (5.27 – 6.56)  
2014 6022 437  0  6.76 (6.05 – 7.53)  
Antipsychotic Medication Use 
2000 7198 50  0 0.54 (0.40 – 0.73)  
2007 6406 47  14 0.62 (0.44 – 0.87)  







Table 3: Odds Ratios for Psychotic Symptoms and Current Antipsychotic Prescription in 2007 and 
2014 compared to 2000  
 	
Year  Unadjusted Odds Ratio 
(OR) (95% CI)  
p-
value  
Adjusted* OR  
(95% CI)  
p-value  
Psychotic Symptoms                                        N= 1,255 out of 20,063  
2000 (Reference)  1    1    
2007  1.06 (0.91 to 1.24)  0.469  1.03 (0.88 to 1.21)  0.726  
2014  1.22 (1.05 to 1.43)  0.012  1.20 (1.02 to 1.40)  0.026  
Antipsychotic Medication Use                      N=186 out of 20,060  
2000 (Reference)  1    1    
2007  1.15 (0.73 to 1.80)  0.550  1.18 (0.75 to 1.85)  0.447  
2014  2.17 (1.47 to 3.20)  <0.001  2.22 (1.52 to 3.25)  <0.001  
		


















 Table 4: Proportion of People with Psychotic Symptoms Taking Antipsychotic Medication by Year 	
Year  Proportion of People with 
Psychotic Symptoms reporting 
Antipsychotic Medication Use  
Proportion (%) 
Proportion of People without 
Psychotic Symptoms reporting 
Antipsychotic Medication Use  
Proportion (%) 
2000  18/418 (3.1)  33/6778 (0.4) 
2007  21/365 (4.4)  28/6010 (0.4) 

























  Table 5: Correlates	of	screening	positive	for	psychotic	symptoms	
Covariate  Category Unadjusted OR (95% 
CI)  







1    1  
  Male  0.90 (0.78 – 1.03)  0.114 0.88 (0.77 – 1.01) 0.070 
Age   
N=20,169 
16-24   
(Reference)  
1      
  25-34  0.67 (0.54 – 0.83)  <0.001*  0.67 (0.54 – 0.84) <0.001* 
  35-44  0.73 (0.59 - 0.90)  0.004* 0.74 (0.60 – 0.92) 0.006 
  45-54  0.58 (0.46 - 0.73)  <0.001*  0.60 (0.48 – 0.76) <0.001* 
  55-64  0.45 (0.35 - 0.58)  <0.001*  0.47 (0.36 – 0.59) <0.001* 
  65-74  0.26 (0.19 - 0.35)  <0.001*  0.28 (0.21 – 0.37) <0.001* 
Ethnicity  
N=20,063 
White British  
(Reference)  
1      
  Black / African / 
Caribbean / Black 
British  
2.22 (1.61 – 3.05)  <0.001*  2.02 (1.46 – 2.78) <0.001* 
  Asian / Asian 
British  
1.49 (1.07 – 2.07)  0.019*  1.26 (0.90 – 1.75) 0.174 
  Mixed / Other 1.22 (0.82 – 1.81)  0.320  1.07 (0.72 – 1.59) 0.748 





1      
  2  1.48 (0.71 – 3.07)  0.294 1.50 (0.73 – 3.10) 0.272 
  3  2.39 (1.13 – 5.06)  0.023*  2.21 (1.05 – 4.62) 0.036* 
  4  1.62 (0.74 – 3.51)  0.244  1.71 (0.78 – 3.73) 0.178 
  5  3.03 (1.45 – 6.33)  0.003*  2.86 (1.37 – 5.95) 0.005* 




of major trauma  
N=12,290 
  2.54 (2.14 – 3.02)  <0.001*  2.62 (2.20 – 3.12) <0.001* 
Any of 15 mental 
illness 
diagnoses from a 
professional 
N=6,469 





schizophrenia by a 
professional 
N=6,479 
  14.98 (7.26 – 30.89)  <0.001*  17.32 (8.37 – 35.82) <0.001* 
Increase in Odds 
per point increase in 
AUDIT b score  
N=18,025 
  1.06 (1.05-1.08)  <0.001 * 1.06 (1.05 – 1.08) <0.001* 
Cannabis use 
in past year  
N=19,674 
  2.71 (2.24 – 3.28)  <0.001 * 2.32 (1.89 – 2.84) <0.001* 
aAUDIT= Alcohol Use Disorders Identification Test  
		
bSocial Class: 1=Employers in large establishments, higher managerial and professional occupations  
2= Lower professional, higher technical, lower managerial and administrative, and higher supervisory 
occupations  
3= Intermediate occupations  
4= Employers in small occupations and own account workers  
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5=Lower supervisory and lower technical occupations  
6 / 7=Semi-routine occupations and routine occupations (Office for National Statistics, 2010)	
  
Adjusted = adjusted for sex, age, and ethnicity. 
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